Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D. | CEO, President & Director | 692.93k | -- | 1963 |
| Ms. Prathyusha Duraibabu CPA, M.B.A. | Senior VP, CFO & Principal Accounting Officer | 470.08k | -- | 1979 |
| Dr. Nathalie Dubois-Stringfellow Ph.D. | Senior VP & Chief Development Officer | 440.97k | -- | 1962 |
| Mr. Gregory Davis Ph.D. | Head of Research & Technology | -- | -- | -- |
| Ms. Aron Feingold | Head of Corporate Communications & Investor Relations Officer | -- | -- | -- |
| Mr. Scott B. Willoughby | Senior VP, General Counsel & Corporate Secretary | -- | -- | 1975 |
| Mr. Phillip Ramsey | Head of Technical Operations | -- | -- | -- |
| Ms. Stephanie J. Seiler CLP | Head of Business Development & Alliance Management | -- | -- | -- |
| Mr. David Ojala | Scientist II - Discovery & Translational Research | -- | -- | -- |
| Ms. Louise Wilkie | Vice President of Investor Relations & Corporate Communications | -- | -- | -- |
Sangamo Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 405
Description
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.
Corporate Governance
Upcoming Events
March 11, 2025 at 12:30 PM UTC - March 17, 2025 at 12:30 PM UTC
Sangamo Therapeutics, Inc. Earnings Date
Recent Events
Recent Events Information Not Available